| 发明名称 |
Dual function fibroblast growth factor 21 proteins |
| 摘要 |
The present invention relates to dual function fusions proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions. |
| 申请公布号 |
US9458214(B2) |
申请公布日期 |
2016.10.04 |
| 申请号 |
US201213626207 |
申请日期 |
2012.09.25 |
| 申请人 |
NOVARTIS AG |
发明人 |
Boettcher Brian R.;Caplan Shari L.;Daniels Douglas S.;Hamamatsu Norio;Licht Stuart;Weldon Stephen Craig;Cellitti Susan E.;Geierstranger Bernhard Hubert;Loew Andreas |
| 分类号 |
A61K38/18;A61K38/26;C07K14/50;C07K14/605 |
主分类号 |
A61K38/18 |
| 代理机构 |
|
代理人 |
Le Hong-Van M. |
| 主权项 |
1. A dual function fusion protein comprising a GLP-1 receptor agonist, a FGF21 receptor agonist, and an Fc domain, attached to each other via a GS linker, and having an orientation of N-terminus-GLP-1 receptor agonist-linker-Fc domain-linker-FGF21 receptor agonist-C-terminus. |
| 地址 |
Basel CH |
